Table 3—

Crude and adjusted odds ratios(ORs) for the risk of chronic thromboembolic pulmonary hypertension

ConditionMarginal effectsPartial effects
OR (95% CI)p-valueOR (95% CI)p-value
Thyroid hormone replacement5.41 (2.70–12.23)<0.0016.10 (2.73–15.05)<0.001
Malignancy1.99 (1.01–4.26)0.0463.76 (1.47–10.43)0.005
Previous VTE19.36 (11.66–33.79)<0.0014.52 (2.35–9.12)<0.001
Recurrent VTE45.02 (21.00–114.73)<0.00114.49 (5.40–43.08)<0.001
Chronic venous ulcers3.17 (1.45–8.17)0.0032.84 (0.99–9.00)0.053
APA/LAC3.28 (1.58–7.50)0.0014.20 (1.56–12.21)0.004
Systemic lupus erythematosus0.06 (0.00–0.48)0.0050.11 (0.00–1.21)0.076
VA shunt or infected pacemaker19.49 (2.47–2520.10)0.00176.40 (7.67–10350.62)<0.001
Inflammatory bowel disease2.21 (0.69–9.05)0.1893.19 (0.74–16.03)0.121
Splenectomy22.09 (2.97–2824.53)<0.00117.87 (1.56–2438.07)0.017
Abnormal haemoglobins7.97 (0.98–1035.53)0.0540.84 (0.05–122.42)0.916
COPD0.26 (0.09–0.73)0.0120.47 (0.12–1.70)0.251
Osteomyelofibrosis1.47 (0.28–14.65)0.6730.34 (0.02–8.48)0.519
  • CI: confidence interval; VTE: venous thromboembolism: APA/LAC: antiphospholipid antibodies/lupus anticoagulant; VA: ventriculo-atrial; COPD: chronic obstructive pulmonary disease.